Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
{ "products": [ { "_id": "6ad74702e53c888beeab308d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliozin 10 mg, Sitagliptin 100 mg and Metformin hydrochloride 1000 mg ER Tablets", "description": "GLIEMPAFLOZIN 3D 10 is a triple-combination antidiabetic tablet containing Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride Extended Release (ER) 1000 mg. This combination is intended for the management of type 2 diabetes mellitus in appropriately selected patients under the supervision of a qualified healthcare professional.\n\nThe three active ingredients work through different mechanisms to help regulate blood glucose levels. Empagliflozin helps the kidneys eliminate glucose through urine, Sitagliptin supports glucose-dependent insulin regulation, and Metformin helps reduce glucose production in the liver while improving insulin sensitivity.\n\nBy combining these ingredients in one tablet, GLIEMPAFLOZIN 3D 10 provides a multi-mechanism approach to blood glucose management. Its suitability depends on the patient's clinical condition, kidney function, existing treatment, and the approved prescribing information.\n\nComposition of GLIEMPAFLOZIN 3D 10\nEach tablet contains the following stated active ingredients:\n\nEmpagliflozin 10 mg: A sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces glucose reabsorption by the kidneys and increases glucose excretion through urine.\nSitagliptin 100 mg: A dipeptidyl peptidase-4 (DPP-4) inhibitor that helps regulate insulin and glucagon responses according to blood glucose levels.\nMetformin Hydrochloride ER 1000 mg: An extended-release biguanide that primarily reduces glucose production in the liver and improves the body's response to insulin.\nThe exact formulation, excipients, approved indications, and administration instructions should be confirmed from the product packaging and official prescribing information.\n\nKey Features of GLIEMPAFLOZIN 3D 10 Tablets\nGLIEMPAFLOZIN 3D 10 combines three established antidiabetic medicines with complementary mechanisms of action.\n\nTriple-combination formulation: Contains Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER.\nMultiple glucose-control pathways: Targets different processes involved in blood glucose regulation.\nExtended-release metformin: Provides a formulation designed to release Metformin gradually over time.\nOral tablet dosage form: Allows administration according to the prescribed regimen.\nIndividualized diabetes management: May be considered when a healthcare professional determines that all three ingredients are appropriate.\nThe combination is not suitable for every person with diabetes. Treatment decisions should be based on individual medical needs and the approved product information.\n\nUses of GLIEMPAFLOZIN 3D 10\nGLIEMPAFLOZIN 3D 10 is intended for the management of type 2 diabetes mellitus, subject to its approved indications and the prescribing healthcare professional's assessment.\n\nType 2 diabetes is a chronic metabolic condition characterized by impaired insulin action and, in many patients, insufficient insulin production. Persistently elevated blood glucose can increase the risk of complications affecting the eyes, kidneys, nerves, heart, and blood vessels.\n\nThe three active ingredients in GLIEMPAFLOZIN 3D 10 address different aspects of glucose regulation. A healthcare professional may consider this combination when multiple medicines are required to achieve an individual's treatment goals and when the combination is clinically appropriate.\n\nThe medicine should be used as part of a comprehensive diabetes-management plan that may include balanced nutrition, regular physical activity, blood glucose monitoring, and routine medical assessments. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.\n\nHow Does GLIEMPAFLOZIN 3D 10 Work?\n1. Empagliflozin 10 mg\nEmpagliflozin belongs to the SGLT2 inhibitor class. It blocks a protein responsible for reabsorbing glucose filtered by the kidneys. This allows more glucose to be eliminated through urine, helping reduce blood glucose levels.\n\nEmpagliflozin has also demonstrated cardiovascular and kidney benefits in certain eligible patient populations. Whether these benefits apply to an individual depends on their clinical condition and the applicable prescribing information.\n\n2. Sitagliptin 100 mg\nSitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. By increasing incretin activity, Sitagliptin supports insulin release when blood glucose is elevated and helps regulate glucagon secretion. These actions contribute to blood glucose control.\n\n3. Metformin Hydrochloride ER 1000 mg\nMetformin primarily reduces glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine gradually over time.\n\nTogether, these ingredients target several pathways involved in type 2 diabetes. Their combined effectiveness and safety depend on appropriate prescribing, correct administration, and regular monitoring.\n\nPotential Benefits of GLIEMPAFLOZIN 3D 10\nWhen prescribed for an appropriate patient, GLIEMPAFLOZIN 3D 10 may offer the following treatment advantages:\n\nMultiple mechanisms of action: Combines three medicines that influence different aspects of glucose regulation.\nBlood glucose management: Helps improve glycemic control in eligible adults with type 2 diabetes.\nCombination therapy: May simplify a treatment regimen compared with taking the same ingredients as separate tablets.\nExtended-release component: Includes Metformin Hydrochloride ER for gradual drug release.\nPersonalized treatment options: May be considered when a healthcare professional determines that triple therapy is appropriate.\nIndividual outcomes vary, and the medicine does not replace a suitable diet, physical activity, or routine diabetes care.\n\nDirections for Use\nTake GLIEMPAFLOZIN 3D 10 only as prescribed by your healthcare professional.\n\nFollow the prescribed dose and administration schedule.\nTake the tablet with food if directed by the product labeling or your prescriber.\nSwallow the extended-release tablet whole unless the specific product instructions state otherwise. Do not crush, chew, or split it without professional guidance.\nDo not change the dose or stop treatment without consulting your prescriber.\nAttend recommended appointments for kidney-function assessment and blood glucose monitoring.\nIf you miss a dose, follow the official patient information or ask your healthcare professional or pharmacist what to do. Do not take an extra dose to compensate for a missed dose unless specifically instructed.\n\nPrecautions and Safety Information\nGLIEMPAFLOZIN 3D 10 is a prescription medicine and may not be suitable for everyone.\n\nKidney function: Kidney function should be assessed before and during treatment as appropriate. Metformin and Empagliflozin have important kidney-related prescribing considerations.\n\nDehydration: Empagliflozin increases glucose excretion through urine and may increase urination. Patients at risk of dehydration or low blood pressure should discuss appropriate precautions with their healthcare professional.\n\nGenital and urinary infections: Empagliflozin may increase the risk of genital fungal infections and can be associated with urinary tract infections.\n\nLactic acidosis: Metformin can rarely cause a serious condition called lactic acidosis. Risk may increase with significant kidney impairment, severe dehydration, certain acute illnesses, or excessive alcohol intake.\n\nPancreatitis: Pancreatitis has been reported in patients taking Sitagliptin. Severe, persistent abdominal pain requires prompt medical assessment.\n\nHypoglycemia: Low blood glucose may occur, particularly when the combination is used with insulin or insulin secretagogues such as sulfonylureas.\n\nInform your healthcare professional about existing medical conditions, all medicines you take, pregnancy or breastfeeding, planned surgery, prolonged fasting, and upcoming procedures involving iodinated contrast. Follow professional instructions about temporary medicine interruption during acute illness or other high-risk situations.\n\nSeek urgent medical care for severe abdominal pain, difficulty breathing, persistent vomiting, severe dehydration, or other serious symptoms.\n\nWhy Choose GLIEMPAFLOZIN 3D 10?\nGLIEMPAFLOZIN 3D 10 brings together Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg in a triple-combination tablet intended for selected patients with type 2 diabetes.\n\nFor pharmaceutical websites, pharmacies, distributors, and healthcare professionals, clear information about composition, mechanism of action, potential uses, and precautions supports responsible product awareness.\n\nAlways refer to the approved product label for the exact composition, indications, dosage, contraindications, storage requirements, and instructions for use.\n\nConclusion\nGLIEMPAFLOZIN 3D 10 Tablets combine Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg to target multiple pathways involved in blood glucose regulation. The combination may be appropriate for selected adults with type 2 diabetes under medical supervision.\n\nFor complete information about dosage, contraindications, warnings, storage, and approved indications, consult the official product packaging and prescribing information. Use this medicine only under the direction of a qualified healthcare professional.\n\nFrequently Asked Questions (FAQs)\n1. What is GLIEMPAFLOZIN 3D 10?\n\nGLIEMPAFLOZIN 3D 10 is a combination tablet containing Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg.\n\n2. What is GLIEMPAFLOZIN 3D 10 used for?\n\nIt is intended for the management of type 2 diabetes mellitus in patients for whom this combination is considered appropriate by a healthcare professional.\n\n3. How does GLIEMPAFLOZIN 3D 10 work?\n\nEmpagliflozin increases urinary glucose excretion, Sitagliptin supports glucose-dependent insulin regulation, and Metformin reduces glucose production in the liver and improves insulin sensitivity.\n\n4. Can GLIEMPAFLOZIN 3D 10 replace diet and exercise?\n\nNo. Medication should be combined with an individualized diet, physical activity, and monitoring plan recommended by a healthcare professional.\n\n5. Is GLIEMPAFLOZIN 3D 10 suitable for everyone with diabetes?\n\nNo. Suitability depends on the type of diabetes, kidney function, other medical conditions, concurrent medicines, and approved prescribing information.\n\n", "price": 210.0, "discountamount": 147.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2505, "imageuri": "https://productimages.withfloats.com/actual/6ad7470422551901df6e5493.png", "tileimageuri": "https://productimages.withfloats.com/tile/6ad7470422551901df6e5493.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-10-20T10:48:34.116Z", "updatedon": "2026-10-20T10:48:34.116Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliozin-10-mg-sitagliptin-100-mg-and-metformin-hydrochloride-1000-mg-er-tablets/2505", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN 3D 10", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6ad7442bf24c5a4bbccf4b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin,Sitagliptin And Metformin Hydrochloride (ER) Tablets", "description": "GLIEMPAFLOZIN 3D 25 is a combination pharmaceutical product containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride Extended Release (ER) 1000 mg. This triple-combination formulation is intended for the management of type 2 diabetes mellitus in appropriate patients, as determined by a qualified healthcare professional.\n\nThe three active ingredients work through different mechanisms to help control blood glucose levels. Empagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin is a biguanide antidiabetic medicine. Together, these ingredients target different pathways involved in glucose regulation.\n\nGLIEMPAFLOZIN 3D 25 provides a combination of three established antidiabetic agents in a single tablet. Its suitability depends on the patient's blood glucose levels, kidney function, current diabetes treatment, medical history, and the approved prescribing information.\n\nComposition of GLIEMPAFLOZIN 3D 25\nEach tablet contains the following stated active ingredients:\n\nEmpagliflozin 25 mg: An SGLT2 inhibitor that helps the kidneys remove glucose from the bloodstream through urine.\nSitagliptin 100 mg: A DPP-4 inhibitor that increases the activity of incretin hormones involved in glucose-dependent insulin release and glucagon regulation.\nMetformin Hydrochloride ER 1000 mg: An extended-release biguanide that primarily reduces glucose production in the liver and improves the body's response to insulin.\nThe exact formulation, excipients, administration instructions, and approved indications should be verified against the product packaging and official prescribing information.\n\nKey Features of GLIEMPAFLOZIN 3D 25\nGLIEMPAFLOZIN 3D 25 combines three antidiabetic ingredients with complementary mechanisms of action.\n\nTriple-combination formulation: Contains Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER.\nMultiple glucose-control pathways: The ingredients act through different mechanisms involved in blood glucose regulation.\nExtended-release metformin: The ER formulation is designed to release metformin over an extended period.\nOral tablet dosage form: Provides oral administration according to the prescribed regimen.\nIndividualized diabetes management: May be considered by a healthcare professional when combination therapy is appropriate.\nThe benefits of this combination depend on the patient's clinical needs and the suitability of all three ingredients.\n\nUses of GLIEMPAFLOZIN 3D 25 Tablets\nGLIEMPAFLOZIN 3D 25 is intended for the management of type 2 diabetes mellitus, subject to the product's approved indications and the prescribing healthcare professional's judgment.\n\nType 2 diabetes is a chronic metabolic condition in which the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood glucose levels. Long-term elevated blood glucose can increase the risk of complications affecting the eyes, kidneys, nerves, heart, and blood vessels.\n\nThe three medicines in GLIEMPAFLOZIN 3D 25 target different aspects of glucose regulation. A healthcare professional may consider a combination regimen when an individual's treatment goals are not adequately achieved with a simpler regimen or when the combination is otherwise clinically appropriate.\n\nThe medicine should be used alongside an individualized diabetes-management plan that may include a balanced diet, physical activity, glucose monitoring, and regular medical follow-up. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.\n\nHow Does GLIEMPAFLOZIN 3D 25 Work?\nThe three active ingredients contribute to blood glucose management through distinct mechanisms.\n\n1. Empagliflozin 25 mg\nEmpagliflozin inhibits SGLT2, a protein responsible for reabsorbing much of the glucose filtered by the kidneys. By reducing glucose reabsorption, it increases glucose excretion through urine and helps lower blood glucose levels.\n\nEmpagliflozin has also demonstrated cardiovascular and kidney benefits in certain eligible patient populations. These benefits depend on the patient's condition and the applicable prescribing information and should not be assumed to apply identically to every patient.\n\n2. Sitagliptin 100 mg\nSitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. Increasing incretin activity helps stimulate insulin release when blood glucose is elevated and reduces glucagon secretion when appropriate. This helps regulate glucose levels, particularly after meals.\n\n3. Metformin Hydrochloride ER 1000 mg\nMetformin primarily decreases glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine gradually over time.\n\nBy combining these mechanisms, GLIEMPAFLOZIN 3D 25 targets several pathways involved in type 2 diabetes. Its overall effectiveness and safety depend on appropriate patient selection, dosing, and ongoing monitoring.\n\nPotential Benefits of GLIEMPAFLOZIN 3D 25\nWhen prescribed for an appropriate patient, this combination may offer the following treatment advantages:\n\nMultiple mechanisms of action: Addresses glucose regulation through three different pharmacological pathways.\nBlood glucose management: Helps improve glycemic control in eligible adults with type 2 diabetes.\nOral combination therapy: Combines three medicines in one tablet, which may simplify a prescribed regimen compared with taking each ingredient separately.\nExtended-release component: Includes Metformin Hydrochloride ER for gradual drug release.\nIndividualized treatment options: May be considered when a healthcare professional determines that all three ingredients are appropriate.\nThese potential advantages do not guarantee a particular result. Treatment effectiveness depends on adherence, diet, physical activity, individual health status, and medical supervision.\n\nDirections for Use\nGLIEMPAFLOZIN 3D 25 should be taken only as prescribed by a qualified healthcare professional.\n\nFollow the prescribed dose and administration schedule.\nTake the tablet with food if directed by the product labeling or prescriber.\nSwallow the extended-release tablet whole unless the specific product instructions state otherwise. Do not crush, chew, or split it without professional guidance.\nDo not change the dose or discontinue treatment without consulting your prescriber.\nAttend recommended appointments for blood glucose monitoring and kidney-function assessment.\nIf a dose is missed, follow the official patient information or ask your healthcare professional or pharmacist for advice. Do not take an extra dose to compensate for a missed dose unless specifically instructed.\n\nPrecautions and Safety Information\nGLIEMPAFLOZIN 3D 25 is a prescription medicine and is not suitable for everyone.\n\nKidney function: Kidney function should be assessed before and during treatment as appropriate. Metformin and Empagliflozin have important renal considerations, and the combination may be unsuitable at certain levels of kidney impairment.\n\nDehydration: Empagliflozin increases glucose excretion through urine and may increase urination. Patients should discuss dehydration risk, low blood pressure, and fluid intake with their healthcare professional.\n\nGenital and urinary infections: Empagliflozin can increase the risk of genital fungal infections and may be associated with urinary tract infections.\n\nLactic acidosis: Metformin can rarely cause a serious condition called lactic acidosis. Risk may increase with significant kidney impairment, severe dehydration, certain acute illnesses, excessive alcohol intake, or other predisposing conditions.\n\nPancreatitis: Pancreatitis has been reported in patients taking Sitagliptin. Severe, persistent abdominal pain requires prompt medical assessment.\n\nLow blood glucose: The risk of hypoglycemia may increase when this combination is used with insulin or insulin secretagogues, such as sulfonylureas.\n\nInform your healthcare professional about existing medical conditions, all medicines you take, pregnancy or breastfeeding, planned surgery, prolonged fasting, or an upcoming medical procedure involving iodinated contrast. Follow professional instructions about temporary medicine interruption during acute illness or other high-risk situations.\n\nSeek urgent medical care for severe abdominal pain, difficulty breathing, unusual weakness, persistent vomiting, severe dehydration, or other serious symptoms.\n\nWhy Choose GLIEMPAFLOZIN 3D 25?\nGLIEMPAFLOZIN 3D 25 brings together Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER in a triple-combination tablet designed for the management of type 2 diabetes in appropriately selected patients.\n\nFor pharmaceutical product catalogues, distributors, pharmacies, and healthcare professionals, accurate information about the composition, mechanism of action, approved indications, and safety profile supports responsible product awareness.\n\nTreatment decisions should always be based on the patient's medical assessment and the approved product information.\n\nConclusion\nGLIEMPAFLOZIN 3D 25 Tablets combine Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg to target multiple pathways involved in blood glucose regulation. This combination may be appropriate for selected adults with type 2 diabetes under medical supervision.\n\nFor complete information about dosage, contraindications, warnings, storage, and approved indications, consult the official product packaging and prescribing information. Use this medicine only under the direction of a qualified healthcare professional.\n\nFrequently Asked Questions (FAQs)\n1. What is GLIEMPAFLOZIN 3D 25?\n\nGLIEMPAFLOZIN 3D 25 is a combination tablet containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg.\n\n2. What is GLIEMPAFLOZIN 3D 25 used for?\n\nIt is intended for the management of type 2 diabetes mellitus in patients for whom the combination is considered appropriate by a healthcare professional.\n\n3. How does GLIEMPAFLOZIN 3D 25 work?\n\nEmpagliflozin increases urinary glucose excretion, Sitagliptin supports glucose-dependent insulin regulation, and Metformin reduces glucose production in the liver and improves insulin sensitivity.\n\n4. Can GLIEMPAFLOZIN 3D 25 replace diet and exercise?\n\nNo. Medication should be combined with an individualized diet, physical activity, and monitoring plan as recommended by a healthcare professional.\n\n5. Is GLIEMPAFLOZIN 3D 25 suitable for everyone with diabetes?\n\nNo. Its suitability depends on the type of diabetes, kidney function, other medical conditions, concurrent medicines, and the approved prescribing information.", "price": 230.0, "discountamount": 69.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2504, "imageuri": "https://productimages.withfloats.com/actual/6ad7442d6e565c5fe6e5b7cb.png", "tileimageuri": "https://productimages.withfloats.com/tile/6ad7442d6e565c5fe6e5b7cb.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-10-20T10:36:27.325Z", "updatedon": "2026-10-20T10:36:27.325Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliflozin-sitagliptin-and-metformin-hydrochloride-er-tablets/2504", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN 3D 25", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a460bf90c11f3c74a816c87", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "methylprednisolone sodium succinate for injection usp", "description": "Methylprednisolone Sodium Succinate for Injection USP is a fast-acting corticosteroid administered intravenously or intramuscularly to control severe inflammation, allergic reactions, and autoimmune flare-ups. It works by rapidly suppressing the immune and inflammatory response and is used in hospital or clinical settings for acute conditions such as severe asthma attacks, anaphylaxis, autoimmune disease flares, and spinal cord injury protocols. It is a Schedule H prescription drug administered only under medical supervision.\n\nWhat Is Methylprednisolone Sodium Succinate for Injection USP?\n\nMethylprednisolone Sodium Succinate for Injection USP is a water-soluble, injectable corticosteroid used for rapid control of severe inflammatory, allergic, and autoimmune conditions. It is manufactured to United States Pharmacopeia (USP) standards and is typically administered by a healthcare professional via intravenous (IV) or intramuscular (IM) route when fast, high-potency anti-inflammatory or immunosuppressive action is required — situations where oral steroids act too slowly or oral intake isn't feasible.\n\nHow It Works\n\nMethylprednisolone sodium succinate is a synthetic glucocorticoid that acts rapidly once reconstituted and injected.\n\n\nBinds glucocorticoid receptors – enters cells and binds intracellular receptors that regulate inflammatory gene expression.\nSuppresses inflammatory mediators – reduces production of prostaglandins, leukotrienes, and cytokines responsible for swelling, redness, and pain.\nStabilizes cell membranes – reduces capillary permeability, limiting fluid leakage and tissue swelling at the site of inflammation.\nDampens immune overactivity – suppresses lymphocyte and macrophage activity, calming autoimmune or allergic overreactions.\nDelivers rapid systemic action – because it's water-soluble and given IV/IM, onset of anti-inflammatory effect is significantly faster than oral steroids.\n\n\nClinical Indications\n\nConditionWhy Methylprednisolone Injection Is UsedSevere Allergic Reactions / AnaphylaxisRapidly controls swelling, airway inflammation, and allergic cascadeAcute Asthma Exacerbation / COPD FlareReduces airway inflammation when inhalers alone are insufficientAutoimmune Disease Flares (Lupus, Rheumatoid Arthritis)High-dose pulse therapy to control acute flaresSpinal Cord Injury (acute, under specialist protocol)Used in specific clinical protocols to limit secondary inflammationSevere Dermatologic ReactionsControls widespread inflammatory skin reactionsPost-Transplant / Organ Rejection ManagementUsed as part of immunosuppressive regimens\n\nDosage & Administration\n\nParameterRecommendationTypical Adult Dose10–40 mg IV, may range up to 30 mg/kg in high-dose pulse therapy for specific conditionsRouteIntravenous (IV) injection/infusion or Intramuscular (IM) injectionFrequencyAs directed by the treating physician; often single dose or short tapering courseReconstitutionMust be reconstituted only with the accompanying diluent as per product insert, immediately before useAdministration SettingHospital, clinic, or under direct medical/nursing supervision onlyDurationShort-term acute use unless otherwise directed; long-term use requires specialist monitoring\n\nThis is a Schedule H prescription-only medicine. Dosage must be determined and administered by a qualified healthcare professional.\n\nPrecautions\n\n\nTo be administered only by or under the supervision of a healthcare professional.\nNot for self-administration or home use.\nInform the doctor of any active infections, as corticosteroids can mask symptoms and suppress immune response.\nUse with caution in patients with diabetes, hypertension, peptic ulcer disease, osteoporosis, or psychiatric history.\nAvoid live vaccines during treatment due to immunosuppressive effects.\nPregnant or breastfeeding patients should use only under strict medical guidance.\nAbrupt discontinuation after prolonged use should be avoided; tapering may be required as advised by the physician.\n\n\nPossible Side Effects\n\nMost side effects relate to the drug's systemic corticosteroid action and are monitored by the administering clinician:\n\n\nElevated blood sugar levels\nFluid retention, increased blood pressure\nMood changes, insomnia, or restlessness\nNausea or gastrointestinal discomfort\nIncreased susceptibility to infection\nInjection site reactions\n\n\nSerious side effects requiring immediate medical attention include severe allergic reaction, signs of infection (fever, chills), significant mood or behavioral changes, unusual swelling, or vision disturbances. Because this is administered in a clinical setting, the healthcare team monitors for these actively.\n\nComparison: Methylprednisolone vs. Other Injectable Corticosteroids\n\nDrugRelative PotencyCommon Use CaseRouteMethylprednisolone Sodium SuccinateHighAcute severe inflammation, autoimmune flaresIV/IMHydrocortisone Sodium SuccinateLowerAdrenal insufficiency, milder acute inflammationIV/IMDexamethasone Sodium PhosphateVery HighCerebral edema, severe allergic/inflammatory conditionsIV/IMBetamethasone Sodium PhosphateHighAllergic and inflammatory conditions, fetal lung maturityIV/IMTriamcinolone AcetonideModerate (depot)Localized/intra-articular inflammationIM/Intra-articular\n\nKey Statistics\n\nStatisticData PointSourceOnset of anti-inflammatory action after IV administrationWithin 1–2 hours for measurable effectClinical pharmacology references, USP monographUse in acute severe asthma protocolsRecommended as part of systemic corticosteroid therapy in emergency guidelinesGlobal Initiative for Asthma (GINA) guidelinesHospital use in anaphylaxis managementIncluded as an adjunct in anaphylaxis treatment protocols alongside epinephrineWorld Allergy Organization guidanceHigh-dose pulse therapy applicationUsed in select autoimmune flare protocols under specialist supervisionPublished rheumatology treatment guidelines\n\nExpert Insight\n\n[Insert verified physician or clinical pharmacologist commentary here — Claude has not fabricated a quote. Recommend sourcing a short, attributable statement from a Steris Healthcare medical advisor or a cited clinical guideline before publishing.]\n\nConclusion\n\nMethylprednisolone Sodium Succinate for Injection USP is a high-potency, fast-acting corticosteroid reserved for situations where rapid control of severe inflammation, allergic reaction, or autoimmune flare is essential. Administered only under clinical supervision, it plays a critical role in emergency and hospital-based treatment protocols — from anaphylaxis and acute asthma to autoimmune disease management. As a Schedule H medicine, it must never be self-administered; dosage, route, and duration should always be determined by a qualified physician based on the patient's condition. For pharmacopoeia-grade quality and reliable hospital supply, source this injection through a WHO-GMP certified manufacturer.\n\nPrescription only – consult your doctor.\n\n\nHigh-Ranking FAQs (Google Search & Voice Search Optimized)\n\n1. What is methylprednisolone sodium succinate injection used for?\nIt is used to rapidly control severe inflammation, allergic reactions, and autoimmune flare-ups, such as anaphylaxis, acute asthma attacks, and lupus or rheumatoid arthritis flares. It is administered under medical supervision in hospital or clinical settings.\n\n2. Is methylprednisolone injection a steroid?\nYes, it is a synthetic corticosteroid (glucocorticoid) that works by suppressing inflammatory and immune responses in the body, providing rapid relief in acute, severe conditions.\n\n3. How is methylprednisolone sodium succinate injection given?\nIt is given by a healthcare professional via intravenous (IV) or intramuscular (IM) injection, after being reconstituted with the correct diluent immediately before administration. It is not for self-injection or home use.\n\n4. How fast does methylprednisolone injection start working?\nBecause it is water-soluble and given directly into the bloodstream or muscle, measurable anti-inflammatory effects typically begin within one to two hours of administration.\n\n5. What are the side effects of methylprednisolone injection?\nCommon effects include elevated blood sugar, fluid retention, mood changes, and increased infection risk. These are monitored by the administering healthcare team, and serious reactions are managed promptly in a clinical setting.\n\n6. Is methylprednisolone sodium succinate injection available without a prescription?\nNo. It is a Schedule H prescription-only medicine that must be administered by or under the direct supervision of a qualified healthcare professional.\n\n7. What is the difference between methylprednisolone and dexamethasone injection?\nBoth are injectable corticosteroids, but dexamethasone has a longer duration of action and higher relative potency, while methylprednisolone is often preferred for acute pulse therapy and shorter-acting systemic control. The choice depends on the clinical scenario and physician judgment.\n\n8. Can methylprednisolone injection be used in pregnancy?\nIt may be used in pregnancy only when clearly necessary and under strict medical supervision, as the treating physician will weigh the benefits against potential risks for the specific condition being treated.", "price": 47.0, "discountamount": 19.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2465, "imageuri": "https://productimages.withfloats.com/actual/6a460bfb9f5529389b8b15b8.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a460bfb9f5529389b8b15b8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-07-02T06:58:01.631Z", "updatedon": "2026-07-02T06:58:01.631Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//methylprednisolone-sodium-succinate-for-injection-usp/2465", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "METHIDENOSOLE 40 INJ", "category": "GENERAL RANGE", "tags": [ "methylprednisolone sodium succinate injection uses", "methylprednisolone sodium succinate injection uses in hindi", "methylprednisolone sodium succinate", "methylprednisolone sodium succinate injection", "inj methylprednisolone sodium succinate", "methylprednisolone sodium succinate uses in hindi", "methylprednisolone sodium succinate for injection", "methylprednisolone sodium succinate injection usp" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69e8bb02806295e2dbefc5e3", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "risedronate sodium tablets ip 35 mg", "description": "Risedronate Sodium Tablets IP 35 mg\n\nMaintaining strong and healthy bones becomes increasingly important with age, especially for individuals at risk of osteoporosis or bone loss. Risedronate Sodium Tablets IP 35 mg is a clinically proven medication widely prescribed to strengthen bones, reduce fracture risk, and improve overall skeletal health. If you are considering this treatment, this buyer-focused guide will help you understand everything—from how it works to its benefits, dosage, precautions, and what to check before purchasing.\n\nWhat are Risedronate Sodium Tablets IP 35 mg?\n\nRisedronate Sodium Tablets IP 35 mg contains risedronate sodium, a medication that belongs to a class called bisphosphonates. These drugs are specifically designed to prevent bone breakdown and increase bone density.\n\nIt is commonly used to treat and prevent the following:\n\nOsteoporosis in postmenopausal women\nOsteoporosis in men\nBone loss due to long-term steroid use\nPaget’s disease of bone\n\nThis once-weekly dosage (35 mg) is convenient and effective for long-term bone health management.\n\nHow Do Risedronate Sodium Tablets IP 35 mg Work?\n\nBones are constantly being renewed through a process called bone remodeling, where old bone is broken down and new bone is formed. In conditions like osteoporosis, bone breakdown occurs faster than formation, leading to weak and fragile bones.\n\nMechanism of Action:\nRisedronate inhibits osteoclasts (cells responsible for bone breakdown)\nSlows down bone loss\nHelps maintain or increase bone density\nReduces the risk of fractures, especially in the spine and hips\n\nBy restoring balance in bone remodeling, this medication strengthens bones over time.\n\nKey Benefits of Risedronate Sodium Tablets IP 35 mg\n1. Strengthens Bones\n\nHelps increase bone mineral density, making bones stronger and less prone to fractures.\n\n2. Reduces Fracture Risk\n\nSignificantly lowers the risk of spine, hip, and other bone fractures.\n\n3. Convenient Weekly Dosage\n\nThe 35 mg tablet is typically taken once a week, improving patient compliance.\n\n4. Effective for Long-Term Use\n\nSuitable for ongoing treatment under medical supervision.\n\n5. Proven Clinical Safety\n\nWidely used and trusted by healthcare professionals worldwide.\n\nWho Should Consider Buying Risedronate Sodium Tablets IP 35 mg?\n\nThis medication is suitable for:\n\nPostmenopausal women at risk of osteoporosis\nMen diagnosed with low bone density\nPatients on long-term corticosteroid therapy\nIndividuals with a history of fractures due to weak bones\nPatients diagnosed with Paget’s disease\n\nImportant: Always consult a healthcare professional before starting this medication.\n\nDosage and Administration\n\nProper usage is crucial to ensure effectiveness and reduce side effects.\n\nGeneral Guidelines:\nUsually taken once weekly (same day each week)\nTake the tablet first thing in the morning\nSwallow with a full glass of plain water (not juice or milk)\nTake on an empty stomach\nImportant Instructions:\nDo not lie down for at least 30 minutes after taking the tablet\nAvoid eating or drinking anything else for 30 minutes\nDo not crush or chew the tablet\n\nFollowing these instructions helps prevent irritation of the esophagus and improves absorption.\n\nPossible Side Effects\n\nLike all medications, Risedronate Sodium Tablets IP 35 mg may cause side effects.\n\nCommon Side Effects:\nStomach pain\nIndigestion\nNausea\nJoint or muscle pain\nLess Common but Serious Side Effects:\nDifficulty swallowing\nSevere chest pain\nJaw pain (rare, associated with osteonecrosis)\nUnusual thigh bone fractures (rare)\n\nIf you experience severe or persistent symptoms, seek medical attention immediately.\n\nPrecautions and Warnings\n\nBefore using this medication, consider the following:\n\nMedical Conditions:\nInform your doctor if you have esophageal disorders\nPatients with kidney problems should use caution\nLow calcium levels should be corrected before starting treatment\nPregnancy and Breastfeeding:\nNot recommended unless prescribed\nConsult your doctor for guidance\nDrug Interactions:\n\nRisedronate may interact with the following:\n\nCalcium supplements\nAntacids\nIron supplements\n\nThese should be taken at a different time of day to avoid interference with absorption.\n\nStorage Instructions\n\nTo maintain the quality of the medication:\n\nStore in a cool, dry place\nKeep away from moisture and sunlight\nMaintain temperature below 25°C\nKeep out of reach of children\nBuying Guide: What to Check Before Purchase\n\nWhen purchasing Risedronate Sodium Tablets IP 35 mg, ensure the following:\n\nIt is prescribed by a qualified doctor\nThe product is from a reputable pharmaceutical brand\nPackaging is intact and properly sealed\nExpiry date is valid\nPurchased from a licensed pharmacy\n\nBulk buyers and distributors should source from trusted suppliers to ensure consistent quality and authenticity.\n\nWhy Choose Risedronate Sodium Tablets IP 35 mg?\n\nThis medication stands out due to:\n\nProven effectiveness in improving bone health\nConvenient once-weekly dosing\nReduced risk of fractures\nLong-term safety when monitored\nCost-effective treatment option\n\nFor individuals seeking reliable osteoporosis management, this tablet offers a practical and effective solution.\n\nFrequently Asked Questions (FAQs)\n1. How long does it take to see results?\n\nBone improvement may take several months, but fracture risk reduction begins earlier.\n\n2. Can I take it daily?\n\nNo, the 35 mg dose is typically taken once weekly.\n\n3. Is it safe for long-term use?\n\nYes, under medical supervision with regular monitoring.\n\n4. Can I take it with food?\n\nNo, it should be taken on an empty stomach for proper absorption.\n\n5. Do I need supplements with this medication?\n\nDoctors often recommend calcium and vitamin D supplements alongside treatment.\n\nLifestyle Tips for Better Bone Health\n\nTo maximize the benefits of Risedronate Sodium Tablets IP 35 mg:\n\nMaintain a calcium-rich diet\nEnsure adequate vitamin D intake\nEngage in weight-bearing exercises\nAvoid smoking and excessive alcohol consumption\nGet regular bone density tests\nConclusion\n\nRisedronate Sodium Tablets IP 35 mg is a trusted and effective solution for managing osteoporosis and improving bone strength. With its proven ability to reduce fracture risk and enhance bone density, it plays a vital role in long-term skeletal health.\n\nFor best results, follow your doctor’s instructions carefully, maintain a healthy lifestyle, and ensure regular medical check-ups. Choosing the right treatment today can significantly improve your bone health and overall quality of life in the future.", "price": 421.0, "discountamount": 127.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2387, "imageuri": "https://productimages.withfloats.com/actual/69e8bb084671736d8a47c29c.png", "tileimageuri": "https://productimages.withfloats.com/tile/69e8bb084671736d8a47c29c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-04-22T12:11:46.043Z", "updatedon": "2026-04-23T06:25:36.613Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//risedronate-sodium-tablets-ip-35-mg/2387", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RISONDROS 35", "category": "ORTHOLOGYRANG", "tags": [ "risedronate sodium tablets ip 35 mg", "risedronate sodium tablets ip 35 mg uses in hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "698d91909e3c03f732124005", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Remogliflozin Etabonate Tablets 100 mg", "description": "REMOFLOZIN 100 is an advanced oral antidiabetic medication containing Remogliflozin Etabonate 100 mg as its active pharmaceutical ingredient. This innovative formulation represents a significant breakthrough in the management of Type 2 Diabetes Mellitus, offering patients a novel mechanism of action that works independently of insulin secretion or insulin sensitivity. REMOFLOZIN 100 belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitors class of medications, which has revolutionized diabetes management by targeting glucose reabsorption in the kidneys rather than affecting pancreatic function or peripheral glucose utilization.\nDeveloped through rigorous scientific research and clinical trials, REMOFLOZIN 100 provides diabetic patients with an effective therapeutic option that not only helps control blood sugar levels but also offers additional cardiovascular and metabolic benefits. Each tablet is precisely formulated to deliver consistent and reliable glycemic control, making it an essential component in the comprehensive management of Type 2 Diabetes.\nHow REMOFLOZIN 100 Works\nThe mechanism of action of REMOFLOZIN 100 is both unique and highly effective. Under normal physiological conditions, the kidneys filter glucose from the blood, but the SGLT2 proteins in the proximal renal tubules reabsorb approximately 90% of this filtered glucose back into the bloodstream. In diabetic patients, this reabsorption continues even when blood glucose levels are elevated, perpetuating hyperglycemia.\nRemogliflozin Etabonate works by selectively inhibiting the SGLT2 proteins in the kidneys, thereby reducing glucose reabsorption and increasing urinary glucose excretion. This insulin-independent mechanism allows the body to eliminate excess glucose naturally through urine, leading to sustained reductions in blood glucose levels. The medication typically begins working within hours of administration, with maximum therapeutic effects observed within several weeks of consistent use.\nPrimary Uses and Indications\nREMOFLOZIN 100 is primarily indicated for:\nManagement of Type 2 Diabetes Mellitus: As monotherapy in patients who cannot tolerate metformin or for whom metformin is contraindicated, and as combination therapy with other antidiabetic agents including metformin, sulfonylureas, or insulin when existing treatment regimens fail to achieve adequate glycemic control.\nGlycemic Control Optimization: For patients requiring additional blood sugar management beyond diet and exercise modifications, REMOFLOZIN 100 helps reduce both fasting plasma glucose and postprandial glucose levels.\nAdjunct to Lifestyle Modifications: The medication works synergistically with dietary modifications and regular physical activity to achieve comprehensive diabetes management and reduce the risk of long-term diabetic complications.\nKey Benefits of REMOFLOZIN 100\nSuperior Glycemic Control\nREMOFLOZIN 100 demonstrates significant efficacy in reducing HbA1c levels, typically achieving reductions of 0.5% to 1.0% when used as monotherapy and even greater reductions when combined with other antidiabetic medications. This improvement in long-term glucose control translates to reduced risk of microvascular complications, including diabetic retinopathy, nephropathy, and neuropathy.\nWeight Management Support\nUnlike many traditional antidiabetic medications that may cause weight gain, REMOFLOZIN 100 is associated with modest weight loss, typically ranging from 2 to 4 kilograms over several months of treatment. This weight reduction occurs due to caloric loss through urinary glucose excretion and may provide additional metabolic benefits for overweight or obese diabetic patients.\nCardiovascular Benefits\nEmerging research on SGLT2 inhibitors suggests potential cardiovascular protective effects, including modest reductions in blood pressure and improvements in various cardiovascular risk markers. These benefits may be particularly valuable for diabetic patients who are at increased risk of cardiovascular disease.\nLow Risk of Hypoglycemia\nBecause REMOFLOZIN 100 works independently of insulin secretion, it carries a minimal risk of hypoglycemia when used as monotherapy. This safety profile makes it particularly suitable for elderly patients or those at higher risk of dangerous low blood sugar episodes.\nRenal Function Considerations\nThe medication may offer nephroprotective benefits by reducing intraglomerular pressure and proteinuria in diabetic patients, potentially slowing the progression of diabetic kidney disease.\nConvenient Once-Daily Dosing\nREMOFLOZIN 100's pharmacokinetic profile allows for convenient once-daily administration, improving patient compliance and treatment adherence.\nPotential Side Effects and Safety Considerations\nWhile REMOFLOZIN 100 is generally well-tolerated, patients should be aware of potential side effects:\nCommon Side Effects\n\nGenital Mycotic Infections: Increased glucose in urine may promote fungal infections, particularly in women\nUrinary Tract Infections: More frequent urination and glucose in urine may increase UTI risk\nIncreased Urination: Polyuria is expected due to the medication's mechanism of action\nThirst: Patients may experience increased thirst due to fluid loss\nDizziness: Particularly when standing up quickly, due to mild blood pressure reductions\n\nSerious but Rare Side Effects\n\nDiabetic Ketoacidosis: Although rare, euglycemic DKA has been reported with SGLT2 inhibitors\nAcute Kidney Injury: Dehydration may affect kidney function in susceptible individuals\nLower Limb Amputation: Some SGLT2 inhibitors have shown increased risk in specific populations\nHypotension: Particularly in patients on diuretics or with compromised cardiovascular function\n\nContraindications and Precautions\nREMOFLOZIN 100 should not be used in patients with type 1 diabetes, severe renal impairment, diabetic ketoacidosis, or those with known hypersensitivity to the drug. Pregnant and breastfeeding women should avoid this medication. Patients should maintain adequate hydration and practice proper genital hygiene to minimize infection risks.\nDosage and Administration Guidelines\nThe standard recommended dose is one REMOFLOZIN 100 tablet taken orally once daily, preferably at the same time each day. The medication can be taken with or without food. Patients should not double doses if they miss a scheduled dose but should take the next dose at the regular time. Dosage adjustments may be necessary based on individual response, renal function, and concomitant medications. Regular monitoring of blood glucose levels, kidney function, and HbA1c is essential for optimal treatment management.\nConclusion\nREMOFLOZIN 100 represents a valuable therapeutic advancement in type 2 diabetes management, offering patients an innovative approach to glycemic control through its unique renal mechanism of action. The medication's ability to reduce blood sugar levels while providing additional benefits such as weight loss, cardiovascular protection, and low hypoglycemia risk makes it an attractive option for many diabetic patients.", "price": 335.0, "discountamount": 101.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2301, "imageuri": "https://productimages.withfloats.com/actual/698d9191cd6033ecce84b352.png", "tileimageuri": "https://productimages.withfloats.com/tile/698d9191cd6033ecce84b352.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-02-12T08:38:40.037Z", "updatedon": "2026-03-13T11:02:30.281Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//remogliflozin-etabonate-tablets-100-mg/2301", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "REMOFLOZIN 100", "category": "DIABETIC RANGE", "tags": [ "Remogliflozin Etabonate 100mg tablets for type 2 diabetes", "Remogliflozin 100mg oral diabetes medication", "Remogliflozin Etabonate tablets 100mg prescription", "Remogliflozin 100 mg SGLT2 inhibitor tablets", "Remogliflozin Etabonate 100mg diabetes control tablets", "Buy Remogliflozin 100mg tablets online", "Remogliflozin Etabonate 100mg pack price", "Remogliflozin 100mg tablets for blood sugar management" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694d181a5837f90c86a7e9f9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Frusemide IP 40mg ", "description": "FRUSIP 40 is a pharmaceutical formulation containing Frusemide IP 40mg as its active ingredient, presented in tablet form for oral administration. This medication belongs to the class of loop diuretics, which are among the most potent diuretic agents available in modern medicine. FRUSIP 40 is specifically designed to help manage conditions associated with fluid retention and elevated blood pressure, offering patients a reliable therapeutic solution for maintaining optimal fluid balance in the body.\nThe formulation adheres to Indian Pharmacopoeia (IP) standards, ensuring consistent quality, purity, and efficacy. Each tablet is precisely manufactured to deliver the exact dosage required for effective treatment while maintaining the highest safety standards in pharmaceutical production.\nUnderstanding Furosemide and Its Mechanism\nFrusemide, also known as furosemide in some regions, is a powerful loop diuretic that works primarily in the kidneys. The medication exerts its therapeutic effect by inhibiting the reabsorption of sodium and chloride in the ascending loop of Henle, a specific segment of the kidney's nephron. This action prevents the body from retaining excess salt and water, leading to increased urine production and the subsequent elimination of accumulated fluids.\nThe “loop” designation comes from the specific site of action within the kidney's loop of Henle, making frusemide significantly more potent than thiazide diuretics that work in different parts of the kidney. This enhanced potency makes FRUSIP 40 particularly valuable in managing conditions requiring substantial fluid removal.\nPrimary Uses and Indications\nFRUSIP 40 is prescribed for various medical conditions where fluid accumulation poses health risks or causes discomfort:\nEdema Management: The medication is highly effective in treating edema (swelling) associated with congestive heart failure, where the heart's reduced pumping efficiency leads to fluid buildup in the lungs, legs, and other tissues. It helps alleviate breathing difficulties and reduces the strain on the cardiovascular system.\nLiver Disease: Patients with cirrhosis or other liver conditions often develop ascites, an accumulation of fluid in the abdominal cavity. FRUSIP 40 helps manage this uncomfortable and potentially dangerous condition by promoting fluid elimination.\nKidney Disorders: In cases of nephrotic syndrome and other renal conditions causing fluid retention, this medication assists in maintaining proper fluid balance, though it must be used judiciously under medical supervision in patients with compromised kidney function.\nHypertension Control: FRUSIP 40 serves as an effective antihypertensive agent, helping to lower blood pressure by reducing blood volume through increased fluid excretion. This is particularly beneficial for patients whose hypertension is resistant to other treatments.\nPulmonary Edema: In acute situations where fluid accumulates in the lungs, this medication can provide rapid relief, making it a valuable tool in emergency medical settings.\nKey Benefits and Therapeutic Advantages\nThe advantages of FRUSIP 40 extend beyond its primary diuretic function, offering patients multiple therapeutic benefits:\nRapid Onset of Action: One of the most significant advantages is the quick response time. Patients typically experience diuretic effects within 30 to 60 minutes of oral administration, with peak effects occurring within one to two hours. This rapid action is particularly valuable in acute situations requiring prompt fluid removal.\nPotent Efficacy: As a loop diuretic, FRUSIP 40 demonstrates superior diuretic potency compared to thiazide diuretics, making it the preferred choice for patients with severe fluid retention or those who haven't responded adequately to milder diuretics.\nCardiovascular Protection: By reducing fluid overload, the medication decreases the workload on the heart, helping to prevent complications in patients with heart failure. This protective effect can significantly improve quality of life and potentially reduce hospitalizations.\nSymptom Relief: Patients often experience notable improvement in symptoms such as shortness of breath, swelling in the extremities, and abdominal distension. This symptomatic relief contributes to enhanced mobility and daily functioning.\nFlexible Dosing: The 40mg strength allows healthcare providers to adjust treatment according to individual patient needs, either maintaining this dose or modifying it based on therapeutic response and tolerance.\nElectrolyte Management: When used under proper medical supervision with appropriate monitoring, the medication allows for controlled fluid management while maintaining awareness of electrolyte balance.\nPotential Side Effects and Considerations\nWhile FRUSIP 40 is generally well-tolerated, patients should be aware of potential side effects:\nCommon Side Effects: These include increased urination frequency (which is expected), dizziness or lightheadedness upon standing (due to reduced blood volume), muscle cramps, and mild headaches. These effects often diminish as the body adjusts to the medication.\nElectrolyte Imbalances: The medication can cause depletion of important electrolytes, including potassium, sodium, magnesium, and calcium. Symptoms may include weakness, irregular heartbeat, confusion, or severe muscle cramps. Regular monitoring through blood tests is essential.\nDehydration Risk: Excessive fluid loss can lead to dehydration, characterized by extreme thirst, dry mouth, decreased urine output, and confusion. Patients must maintain adequate fluid intake as directed by their healthcare provider.\nMetabolic Effects: Some patients may experience increased blood sugar levels, elevated uric acid (potentially triggering gout attacks), or changes in cholesterol levels.\nHearing Changes: Rarely, particularly at higher doses, patients may experience ringing in the ears (tinnitus) or temporary hearing impairment.\nPhotosensitivity: Increased sensitivity to sunlight may occur, requiring appropriate sun protection measures.\nDrug Interactions: FRUSIP 40 can interact with numerous medications, including certain antibiotics, other blood pressure medications, NSAIDs, and lithium, necessitating comprehensive medication review by healthcare providers.\nImportant Safety Information\nPatients taking FRUSIP 40 should inform their healthcare provider about any existing medical conditions, particularly kidney disease, liver disease, diabetes, gout, or lupus. Pregnant and breastfeeding women require special consideration, as the medication crosses the placenta and appears in breast milk.\nRegular monitoring of kidney function, electrolyte levels, and blood pressure is essential for safe and effective therapy. Patients should maintain consistent communication with their healthcare team and report any unusual symptoms promptly.\nConclusion\nFRUSIP 40 (Frusemide IP 40mg Tablets) represents a cornerstone therapy in the management of conditions involving fluid retention and hypertension. Its potent diuretic action, rapid onset, and proven efficacy make it an invaluable tool in cardiovascular and renal medicine. The medication offers significant benefits in symptom relief, cardiovascular protection, and overall quality of life improvement for patients struggling with edema and related conditions.\nHowever, the power of this medication demands respect and proper medical supervision. The potential for electrolyte imbalances and other side effects necessitates regular monitoring and open communication between patients and healthcare providers. When used appropriately under medical guidance, with proper monitoring and patient education, FRUSIP 40 can dramatically improve patient outcomes and help individuals regain control over conditions that significantly impact their daily lives.\nPatients prescribed FRUSIP 40 should view this medication as part of a comprehensive treatment plan that may include dietary modifications, lifestyle changes, and other medications. Success with this therapy depends on adherence to prescribed dosing, regular follow-up appointments, and proactive management of potential side effects. With proper use, FRUSIP 40 continues to serve as a trusted and effective therapeutic option for millions of patients worldwide requiring diuretic therapy.", "price": 14.0, "discountamount": 5.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2255, "imageuri": "https://productimages.withfloats.com/actual/694d1821ad363997d8b04dfb.png", "tileimageuri": "https://productimages.withfloats.com/tile/694d1821ad363997d8b04dfb.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T10:55:22.405Z", "updatedon": "2026-04-18T09:37:29.473Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//frusemide-ip-40mg-/2255", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "FRUSIP 40", "category": "UROLOGYRANGE", "tags": [ "FRUSIP 40", "It helps alleviate breathing difficulties and reduces the strain on the cardiovascular system.", "fluid buildup in the lungs, legs, and other tissues.", "Metabolic Effects.", "frusemide 40mg", "tab frusemide 40mg", "frusemide 40mg use", "frusemide 40mg hindi", "frusemide 40mg tablet", "frusemide 40mg uses", "frusemide 40mg price", "tab frusemide 40mg use" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b6d6c76f14ecfa6add5d56", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sacubitril and Valsartan Tablets 97 mg + 103 mg", "description": "Description: \nSACUSMART 200 is a combination medicine containing Sacubitril (97 mg) and Valsartan (103 mg), specifically designed to manage chronic heart failure with reduced ejection fraction (HFrEF). This dual-acting therapy is classified as an angiotensin receptor neprilysin inhibitor (ARNI) and is widely prescribed to reduce the risk of cardiovascular death and hospitalization in patients with heart failure.\n\nHeart failure is a progressive condition where the heart cannot pump blood efficiently to meet the body’s needs. SACUSMART 200 improves the efficiency of the heart by relaxing blood vessels, reducing fluid retention, and lowering strain on the heart, helping patients live a better and longer life.\n\nWhat is SACUSMART 200?\nSACUSMART 200 is a highly effective heart failure medication that combines two active components:\nSacubitril (97 mg) – a neprilysin inhibitor that increases levels of natriuretic peptides, leading to vasodilation, sodium excretion, and reduced stress on the heart.\n\nValsartan (103 mg) – an angiotensin II receptor blocker (ARB) that relaxes blood vessels, lowers blood pressure, and prevents harmful effects of angiotensin II.\nTogether, these mechanisms make SACUSMART 200 a superior alternative to traditional ACE inhibitors or ARBs alone in treating chronic heart failure.\nUses of SACUSMART 200\nSACUSMART 200 is prescribed for:\nChronic heart failure with reduced ejection fraction (HFrEF)\nReducing risk of hospitalization due to worsening heart failure\nImproving survival rates in patients with heart failure\nEnhancing exercise tolerance and quality of life in long-term heart failure management\nBenefits of SACUSMART 200\nDual action with neprilysin inhibition + ARB effect for comprehensive heart protection\nProven to reduce mortality and hospitalization risk in heart failure patients\n\nImproves symptoms such as breathlessness, fatigue, and swelling\nHelps patients regain better physical stamina and daily activity levels\nLong-term use significantly contributes to improved quality of life\nPossible Side Effects of SACUSMART 200.\nWhile SACUSMART 200 is effective and generally well tolerated, some patients may experience:\nLow blood pressure (hypotension)\nIncreased blood potassium levels (hyperkalemia)\nDizziness or light-headedness\nKidney function changes\nCough\nRarely, serious allergic reactions or angioedema (swelling of face, lips, or throat)\nImmediate medical attention is required if severe swelling, difficulty breathing, or fainting occurs.\nPrecautions Before Using SACUSMART 200.\nDo not use if you are allergic to sacubitril, valsartan, or other ARBs\nAvoid if you have taken an ACE inhibitor within the last 36 hours due to the risk of angioedema\nNot recommended for patients with a history of hereditary angioedema\nCaution in patients with severe kidney or liver disease\nPregnant and breastfeeding women should avoid this medicine due to harmful effects on the baby\nAlways monitor blood pressure, kidney function, and potassium levels while on this treatment\nDrug Interactions.\nSACUSMART 200 may interact with:\n\nACE inhibitors – should not be combined, risk of angioedema\n\nPotassium supplements or potassium-sparing diuretics – risk of high potassium\n\nNSAIDs (e.g., ibuprofen, naproxen) – may reduce kidney function\n\nLithium – risk of lithium toxicity\n\nDiuretics – may increase the risk of low blood pressure\n\nAlways inform your doctor about all medicines, supplements, or herbal products you are taking before starting SACUSMART 200.\n\n \nConclusion\n \n\nSACUSMART 200 (Sacubitril 97 mg & Valsartan 103 mg) is a breakthrough treatment in managing chronic heart failure with reduced ejection fraction (HFrEF). By combining neprilysin inhibition and angiotensin receptor blockade, it not only reduces symptoms but also significantly lowers the risk of hospitalization and death, improving both longevity and quality of life.\n\nFor patients living with heart failure, SACUSMART 200 offers a scientifically proven and clinically superior solution to regain control over their health and live a more fulfilling life.", "price": 750.0, "discountamount": 225.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2170, "imageuri": "https://productimages.withfloats.com/actual/68b6d6c9c4087f14f55d7d23.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b6d6c9c4087f14f55d7d23.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-02T11:36:39.17Z", "updatedon": "2026-05-25T06:41:35.287Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//sacubitril-and-valsartan-tablets-97-mg-103-mg/2170", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SACUSMART 200", "category": "CARDIOLOGYRANGE", "tags": [ "Sacubitril 97 mg and Valsartan 103 mg", "sacubitril and valsartan tablets uses", "sacubitril and valsartan tablets benefits", "sacubitril valsartan tablet dosage", "sacubitril and valsartan tablet mechanism of action", "sacubitril valsartan tablets side effects", "sacubitril valsartan tablet how it works", "sacubitril and valsartan tablets price in India", "sacubitril valsartan tablets manufacturer in India", "sacubitril and valsartan tablets brand name", "best sacubitril and valsartan tablets in India", "sacubitril valsartan tablets wholesale supplier", "what is sacubitril and valsartan tablet used for", "who should take sacubitril valsartan tablets", "sacubitril and valsartan tablets", "sacubitril and valsartan tablets 50 mg", "sacubitril and valsartan tablets uses in hindi", "uses of sacubitril and valsartan tablets", "sacubitril and valsartan tablets in hindi", "rx sacubitril and valsartan tablets", "sacubitril and valsartan tablets 100mg", "sacubitril and valsartan tablets in india", "sacubitril and valsartan tablets 100mg", "sacubitril and valsartan tablets in india", "use of sacubitril and valsartan tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin and Linagliptin Tablets", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 324.0, "discountamount": 97.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/69de144aff27708f32d3a9ea.png", "tileimageuri": "https://productimages.withfloats.com/tile/69de144aff27708f32d3a9ea.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2026-05-23T07:06:09.535Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliflozin-and-linagliptin-tablets/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EMPATECH LINA 25/5", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets", "help manage blood sugar levels", "2 diabetes mellitus", "Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2)", "fixed dose combination of empagliflozin and linagliptin tablets", "empagliflozin and linagliptin tablets uses", "empagliflozin and linagliptin tablets 25 mg", "empagliflozin 25 mg uses in hindi", "empagliflozin side effects", "fixed dose combination of empagliflozin and linagliptin tablets", "empagliflozin and linagliptin tablets uses", "empagliflozin and linagliptin uses in hindi", "empagliflozin and linagliptin uses", "fixed dose combination of empagliflozin and linagliptin tablets", "empagliflozin and linagliptin", "empagliflozin and linagliptin brands in india", "empagliflozin and linagliptin tablets uses", "empagliflozin and linagliptin brands", "empagliflozin and linagliptin tablet uses", "empagliflozin and linagliptin combination", "combination of empagliflozin and linagliptin", "empagliflozin and linagliptin tablet" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "683d992c87328f4e892f8716", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin 25 mg", "description": "EMPATECH 25 is an advanced oral medication formulated with Empagliflozin 25 mg, a trusted and effective treatment for managing Type 2 Diabetes Mellitus (T2DM). It is part of a class of drugs known as SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors), designed to help lower blood sugar levels in adults when used alongside proper diet and exercise. EMPATECH 25 not only improves glycemic control but also contributes to weight management and cardiovascular health in diabetic patients.\n\nKey Ingredients\nEmpagliflozin 25 mg: A selective SGLT2 inhibitor that helps remove excess glucose from the body through urine, lowering blood sugar levels in patients with type 2 diabetes.\n\nKey Benefits\nHelps significantly reduce elevated blood glucose (HbA1c) levels in Type 2 Diabetes\n\nSupports weight loss by reducing excess sugar stored in the body\n\nAids in lowering systolic blood pressure\n\nDemonstrated cardiovascular benefits, including reduced risk of heart failure hospitalization\n\nEnhances overall glycemic control without causing hypoglycemia when used alone\n\nConvenient once-daily oral dosing\n\nHow Does It Work?\nEmpagliflozin blocks the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream.\n\nBy inhibiting this protein, the medication increases glucose excretion through urine, thereby lowering blood sugar levels.\n\nIt works independently of insulin, making it a suitable option even when insulin resistance is present.\n\nAdditionally, this mechanism reduces blood pressure and body weight, offering multiple metabolic benefits beyond blood sugar control.\n\nDirections for Use\nTake one tablet of EMPATECH 25 orally once a day, preferably at the same time each day.\n\nIt can be taken with or without food.\n\nFollow the dosage as prescribed by your healthcare provider.\n\nDo not crush, chew, or break the tablet; swallow it whole with water.\n\nMaintain regular blood sugar monitoring and adhere to a balanced diet and exercise regimen.\n\nSide Effects\nIncreased urination\n\nGenital infections (e.g., yeast infections)\n\nUrinary tract infections (UTIs)\n\nThirst and mild dehydration\n\nLow blood pressure (especially in people on diuretics)\n\nDizziness or lightheadedness\n\nPossible increase in cholesterol levels\n\nIn rare cases, ketoacidosis (seek immediate medical attention if symptoms like nausea, vomiting, or abdominal pain occur)", "price": 211.0, "discountamount": 63.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "tablet swallow", "day preferably", "body aids", "nausea vomiting", "medical attention", "cholesterol levels", "diuretics dizziness", "crush chew", "healthcare provider", "food follow", "empatech 25 orally", "present additionally", "insulin resistance", "suitable option", "insulin making", "works independently", "sglt2 protein", "causing hypoglycemia", "reduced risk", "cardiovascular health", "weight management", "exercise empatech 25", "effective treatment", "empatech 25empatech 25", "balanced diet", "empagliflozin 25 mg", "glycemic control", "improves glycemic control", "work empagliflozin blocks", "selective sglt2 inhibitor", "alongside proper diet", "abdominal pain occur", "reabsorbing glucose back" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2130, "imageuri": "https://productimages.withfloats.com/actual/683d99313e1ed3094cddca21.png", "tileimageuri": "https://productimages.withfloats.com/tile/683d99313e1ed3094cddca21.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-02T12:29:32.123Z", "updatedon": "2026-03-13T10:22:19.583Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliflozin-25-mg/2130", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EMPATECH 25", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 25 mg", "empagliflozin 25 mg tablet", "Empagliflozin 25 mg brands in India", "Empagliflozin 25 mg Price in India", "blood sugar levels.", "help lower blood sugar.", "cardiovascular health in diabetic patients." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }

Still searching for
sodium excretion?

Still searching for
sodium excretion?

Chat with us